Clinical Trials Browser

Phase 2 × Carcinoma, Ovarian Epithelial × Immunoenzyme Techniques × Clear all

NCT00522301 2016-02-29

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Phase 2 Terminated

6 enrolled 5 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms